Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
Sign Up to like & getrecommendations! Published in 2018 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.8b00213
Abstract: GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets and enteroendocrine L-cells, and, when activated, elicits increased insulin secretion only in the presence of elevated glucose levels. We recently reported the discovery of… read more here.
Keywords: gpr40; discovery 6226; full agonist; gpr40 full ... See more keywords
Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Toxicology"
DOI: 10.1080/15563650.2022.2028802
Abstract: Abstract Introduction Patients with opioid use disorder may have difficulty transitioning from full-agonist opioids to sublingual buprenorphine due to the risk of precipitated opioid withdrawal. Novel strategies have been developed to facilitate this transition, including… read more here.
Keywords: sublingual buprenorphine; transdermal buprenorphine; buprenorphine; full agonist ... See more keywords
Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of addiction medicine"
DOI: 10.1097/adm.0000000000001136
Abstract: OBJECTIVES Persons with opioid use disorder (OUD) suffer disproportionately from morbidity and mortality related to serious addiction-related infections requiring hospitalization. Long-acting buprenorphine (LAB) is an underused medication for OUD that may facilitate linkage to care… read more here.
Keywords: including methadone; agonist opioids; low dose; buprenorphine ... See more keywords